Hepatitis C incidence has been shown to be increased in chronic fatigue syndrome patients.
Prevalence[edit | edit source]
It is estimated that between 130-200 million people worldwide have a hepatitis C infection, occurring most commonly in Africa and Central and East Asia. In 2013, hepatitis C was the cause of around 358,000 deaths due to cirrhosis and 343,000 deaths due to liver cancer.
Transmission[edit | edit source]
Signs and symptoms[edit | edit source]
Diagnosis[edit | edit source]
Hepatitis C in Chronic Fatigue Syndrome[edit | edit source]
Notable studies[edit | edit source]
Potential treatments[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- Siu, Gavin Ka Yu; Zhou, Fan; Yu, Mei Kuen; Zhang, Leiliang; Wang, Tuanlao; Liang, Yongheng; Chen, Yangchao; Chan, Hsiao Chang; Yu, Sidney (2016), "Hepatitis C virus NS5A protein cooperates with phosphatidylinositol 4-kinase IIIα to induce mitochondrial fragmentation", Scientific Reports 6, doi:10.1038/srep23464
- "Hepatitis C Fact sheet N°164", WHO, July 2015, retrieved Feb 4, 2016
- GBD 2013 Mortality and Causes of Death, Collaborators (Dec 17, 2014), "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.", Lancet, 385 (9963): 117–71, doi:10.1016/S0140-6736(14)61682-2, PMC , PMID 25530442